EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte Studie

High-dose (40 mg) versus low-dose (20 mg) prednisolone for treating sarcoidosis: a randomised trial (SARCORT trial)

Sahajal Dhooria iD, Inderpaul Singh Sehgal iD, Ritesh Agarwal, Valliappan Muthu, Kuruswamy Thurai Prasad, Pooja Dogra, Uma Debi, Mandeep Garg, Amanjit Bal iD, Nalini Gupta, Ashutosh Nath Aggarwal

European Respiratory Journal · 2023-09 · 62 (3) · 2300198

DOI: 10.1183/13993003.00198-2023 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift European Respiratory Journal, online erschienen am 09.09.2023. Verfasst von Sahajal Dhooria und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pulmonary Medicine, Postgraduate Institute of Medical Education and Research (PGIMER), Chandigarh, India sahajal@gmail.com. Hauptthemen laut MEDLINE: Prednisolone, Sarcoidosis, Pulmonary. Die Arbeit wurde bisher 73-mal zitiert (Crossref) und nennt 41 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Current guidelines recommend 20–40 mg·day −1 of oral prednisolone for treating pulmonary sarcoidosis. Whether the higher dose (40 mg·day −1 ) can improve outcomes remains unknown.

Methods

We conducted an investigator-initiated, single-centre, open-label, parallel-group, randomised controlled trial ( ClinicalTrials.gov identifier NCT03265405 ). Consecutive subjects with pulmonary sarcoidosis were randomised (1:1) to receive either high-dose (40 mg·day −1 initial dose) or low-dose (20 mg·day −1 initial dose) oral prednisolone, tapered over 6 months. The primary outcome was the frequency of relapse or treatment failure at 18 months from randomisation. Key secondary outcomes included the time to relapse or treatment failure, overall response, change in forced vital capacity (FVC, in litres) at 6 and 18 months, treatment-related adverse effects and health-related quality of life (HRQoL) scores using the Sarcoidosis Health Questionnaire and Fatigue Assessment Scale.

Findings

We included 86 subjects (43 in each group). 42 and 43 subjects completed treatment in the high-dose and low-dose groups, respectively, while 37 (86.0%) and 41 (95.3%), respectively, completed the 18-month follow-up. 20 (46.5%) subjects had relapse or treatment failure in the high-dose group and 19 (44.2%) in the low-dose group (p=0.75). The mean time to relapse/treatment failure was similar between the groups (high-dose 307 days versus low-dose 269 days, p=0.27). The overall response, the changes in FVC at 6 and 18 months and the incidence of adverse effects were also similar. Changes in HRQoL scores did not differ between the study groups.

Interpretation

High-dose prednisolone was not superior to a lower dose in improving outcomes or the HRQoL in sarcoidosis and was associated with similar adverse effects.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PrednisoloneSarcoidosis, PulmonaryHumansQuality of LifeYoung AdultAdult

Substanzen

Prednisolone

Autor:innen und Institutionen

  • Department of Pulmonary Medicine, Postgraduate Institute of Medical Education and Research (PGIMER), Chandigarh, India sahajal@gmail.com.
  • Department of Pulmonary Medicine, Postgraduate Institute of Medical Education and Research (PGIMER), Chandigarh, India.
  • Department of Radiodiagnosis and Imaging, Postgraduate Institute of Medical Education and Research (PGIMER), Chandigarh, India.
  • Department of Histopathology, Postgraduate Institute of Medical Education and Research (PGIMER), Chandigarh, India.
  • Department of Cytology and Gynecologic Pathology, Postgraduate Institute of Medical Education and Research (PGIMER), Chandigarh, India.

ORCID-Profile: Sahajal Dhooria, Inderpaul Singh Sehgal, Amanjit Bal

Zitieren

APA

Dhooria, S., Sehgal, I. S., Agarwal, R., Muthu, V., Prasad, K. T., Dogra, P., Debi, U., Garg, M., Bal, A., Gupta, N., & Aggarwal, A. N. (2023). High-dose (40 mg) versus low-dose (20 mg) prednisolone for treating sarcoidosis: a randomised trial (SARCORT trial). European Respiratory Journal, 62(3), 2300198. https://doi.org/10.1183/13993003.00198-2023

Vancouver

Dhooria S, Sehgal IS, Agarwal R, Muthu V, Prasad KT, Dogra P, et al. High-dose (40 mg) versus low-dose (20 mg) prednisolone for treating sarcoidosis: a randomised trial (SARCORT trial). European Respiratory Journal. 2023;62(3):2300198. doi:10.1183/13993003.00198-2023

BibTeX
@article{Dhooria2023,
  author = {Dhooria, Sahajal and Sehgal, Inderpaul Singh and Agarwal, Ritesh and Muthu, Valliappan and Prasad, Kuruswamy Thurai and Dogra, Pooja and Debi, Uma and Garg, Mandeep and Bal, Amanjit and Gupta, Nalini and Aggarwal, Ashutosh Nath},
  title = {High-dose (40 mg) versus low-dose (20 mg) prednisolone for treating sarcoidosis: a randomised trial (SARCORT trial)},
  journal = {European Respiratory Journal},
  year = {2023},
  volume = {62},
  number = {3},
  pages = {2300198},
  doi = {10.1183/13993003.00198-2023}
}
Kostenlos starten →